This Canadian biotech stock will beat the market, analyst says

In a March 10 update, Leede analyst Douglas Loe maintained a “Speculative Buy” rating and US$16.00 target on Satellos Bioscience (Satellos Bioscience Stock Quote, Chart, News, Analysts, Financials TSX:MSCL, NASDAQ:MSLE) following the company’s latest interim clinical update for its Duchenne muscular dystrophy (DMD) program.

Loe said the Ontario-based rare-disease drug developer recently reported updated interim Phase II data from its TRAILHEAD trial, a 30-patient adult DMD study evaluating SAT-3247, an orally active small-molecule drug designed to inhibit adaptor-associated protein kinase 1 (AAK1). The update included multiple efficacy endpoints, including biomarkers related to disease physiology, muscle function in patients and measures of muscle regeneration presented in posters at a U.S.-based muscular dystrophy scientific conference.

Loe said the capital markets response to the update appeared “somewhere between ambiguous and negative,” which he suggested may partly reflect profit-taking after the company’s shares rose about 93% over the past six months. He added that the data itself appeared “more evolutionary than revolutionary” in terms of advancing the clinical case for SAT-3247.

Still, Loe said the TRAILHEAD results, including data from four evaluable patients, raised questions about the drug’s mechanism of action, suggesting there may be a threshold of residual muscle function above which the therapy may improve outcomes and below which it may be less effective.

Despite the mixed initial reaction, Loe said the update does not materially change his investment thesis.

“Maintaining our core investment thesis on Satellos, notwithstanding today’s share price compression on what we consider to be evolutionary insights into our conceptualization of SAT-3247’s medical prospects,” he wrote.

Loe expects further updates from both the 10-patient adult TRAILHEAD study and the 51-patient pediatric Phase II BASECAMP trial, which began enrolling patients last month. He said interim updates through fiscal 2026 are likely to provide incremental but not definitive evidence of efficacy, with final data from Phase II and eventual Phase III trials required for regulatory review.

Loe’s US$16.00 target price is based on a discounted net present value model using a 30% discount rate and multiples of his 2031 forecasts for US$81.0-million in EBITDA and US$2.53 per share in fully diluted earnings. His valuation assumes pro forma cash of US$88.1-million, reflecting fiscal third-quarter cash of US$34.6-million plus proceeds from a February 2026 equity financing, and no long-term debt, based on 23.3-million fully diluted shares outstanding.

The analyts forecasts Satellos will report negative Adjusted EBITDA of $22.1-million in fiscal 2025, widening to negative $25.0-million in fiscal 2026, with no revenue expected in either year as the company continues to advance its clinical programs.

-30-